Cytokinetics, Incorporated (CYTK)

Over the past six months, Cytokinetics' stock has experienced significant events. The stock price has shown a substantial increase over the past year, with a 52-week range between $29.31 and $80.20. The FDA approved MYQORZO in December 2025, followed by its U.S. commercial launch in January 2026, and the European Commission (EC) also approved MYQORZO. In May 2026, positive topline results from the ACACIA-HCM trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) were announced, contributing to a stock surge. Cytokinetics raised $760 million in a stock offering in May 2026. In April and May 2026, some senior executives sold shares, though they still retain sizable stakes. The company reported its first-quarter 2026 financial results in May 2026, highlighting strong demand for MYQORZO in its initial U.S. launch.

There is no specific information available in the provided search results regarding demand seasonality for Cytokinetics, Inc.'s products and services.

Cytokinetics, Inc. is a late-stage, specialty cardiovascular biopharmaceutical company focused on muscle biology-directed drug candidates for cardiovascular and neuromuscular diseases. Key products include MYQORZO (aficamten), an oral cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and being evaluated for non-obstructive hypertrophic cardiomyopathy (nHCM). Other candidates include omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), reldesemtiv for ALS, CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for muscular dystrophy and impaired skeletal muscle function.

Cytokinetics, Inc. is headquartered in South San Francisco, California, U.S. The company has a growing international presence, with MYQORZO approved and launched in the U.S., approved in the European Union, and approved in China. European commercial readiness activities are underway, with the first European launch planned in Germany in Q2 2026.

Cytokinetics has generally maintained a positive brand reputation, driven by clinical advancements and product approvals. The FDA approval of MYQORZO in late 2025 and its subsequent commercial launch in early 2026 marked a significant positive inflection point. Positive topline results from the ACACIA-HCM trial in May 2026 further bolstered its reputation and market confidence. Analysts have a consensus "Buy" rating for CYTK, and the company actively engages with the hypertrophic cardiomyopathy community.

Approximately 63.39% of Cytokinetics' stock is owned by institutional investors, 0.85% by insiders, and 35.76% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Fmr Llc, Vanguard Group Inc., T. Rowe Price Investment Management, Inc., State Street Corp, Deep Track Capital, LP, Geode Capital Management, Llc, Bank Of America Corp /de/, Rtw Investments, Lp, Polar Capital Holdings Plc, Dimensional Fund Advisors LP, and Meeder Advisory Services Inc.